Table 3. Most Common Adverse Event Categories for Which Grade 3 and Grade 4 Toxic Effects Were Reported Among 42 Patientsa.
| Adverse effect | Patients, No. (%) | |||||
|---|---|---|---|---|---|---|
| Before conditioning | Any time during treatment | |||||
| Grades 1 and 2 | Grades 3 and 4 | Total | Grades 1 and 2 | Grades 3 and 4 | Total | |
| Anemia | 20 (48) | 20 (48) | 40 (95) | 9 (21) | 32 (76) | 41 (98) |
| ALC decreased | 15 (36) | 24 (57) | 39 (93) | 2 (5) | 39 (93) | 41 (98) |
| Platelet count decreased | 8 (19) | 32 (76) | 40 (95) | 1 (2) | 40 (95) | 41 (98) |
| WBC count decreased | 12 (29) | 17 (40) | 29 (69) | 1 (2) | 39 (93) | 40 (95) |
| Neutropenia | 5 (12) | 15 (36) | 20 (48) | NA | 38 (91) | 38 (91) |
| Nausea | 29 (69) | NA | 29 (69) | 34 (81) | 1 (2) | 35 (83) |
| Elevated AST or ALT | 26 (62) | 2 (5) | 28 (67) | 29 (69) | 4 (10) | 33 (79) |
| Hypoalbuminemia | 26 (62) | NA | 26 (62) | 32 (76) | 1 (2) | 33 (79) |
| Hypokalemia | 13 (31) | 4 (10) | 17 (45) | 17 (40) | 16 (38) | 33 (79) |
| Hyperglycemia | 28 (67) | 1 (2) | 29 (69) | 29 (69) | 3 (7) | 32 (76) |
| Hypocalcemia | 22 (52) | NA | 22 (52) | 29 (69) | 2 (5) | 31 (74) |
| Diarrhea | 5 (12) | 1 (2) | 6 (14) | 28 (67) | 1 (2) | 29 (69) |
| Hypophosphatemia | 7 (17) | 3 (7) | 10 (24) | 13 (31) | 11 (26) | 24 (57) |
| Hypertension | 14 (33) | 4 (10) | 18 (43) | 17 (40) | 6 (14) | 23 (55) |
| Hyponatremia | 14 (33) | NA | 14 (33) | 17 (40) | 3 (7) | 20 (48) |
| Mucositis | NA | NA | NA | 10 (24) | 10 (24) | 20 (48) |
| Fatigue | 12 (29) | 1 (2) | 13 (31) | 16 (38) | 1 (2) | 17 (40) |
| Hypotension | 3 (7) | NA | 3 (7) | 13 (31) | 2 (5) | 15 (36) |
| Abdominal pain | 5 (12) | NA | 5 (12) | 13 (31) | 1 (2) | 14 (33) |
| Febrile neutropenia | NA | NA | NA | NA | 12 (29) | 12 (29) |
Abbreviations: ALC, absolute lymphocyte count; ALT, alanine aminotransferase; AST, aspartate aminotransferase; NA, not available; WBC, white blood cell.
a
All patients who received at least 1 dose of pembrolizumab were eligible for toxic effects analysis. There were 2 grade 5 events: 1 patient with unsuspected severe coronary artery disease had cardiac arrest during apheresis, and 1 patient died of respiratory failure suspected to represent engraftment syndrome.